Altasciences Acquires WCCT Global
- Wall Street slips off record highs, Tesla drops after fatal crash
- IBM (IBM) Tops Q1 EPS by 14c, Revenue Beats
- Tesla's (TSLA) Musk says data logs from crashed vehicle show Autopilot was not enabled, car did not purchase FSD
- Bitcoin (BTC) Price Fell 20% Off the Highs Over the Weekend as Markets Got 'Too Excited' About Coinbase (COIN), Says Mike Novogratz
- GameStop (GME) CEO Gets the Axe as Ryan Cohen Continues to Make His Mark, Analyst Says Co. Will Likely Look to Tech Sector for New Hires
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
LAVAL, Quebec--(BUSINESS WIRE)-- Altasciences announced today that they have acquired WCCT Global, Inc., an early stage clinical research organization, or CRO, located in Southern California on the U.S.A.’s West Coast. This acquisition will complement Altasciences’ current clinical operations in Montreal, Canada, and Kansas City, U.S.A., while being in close proximity to their Washington State preclinical facility.
“This acquisition expands Altasciences’ footprint by providing Phase I and II clinical pharmacology services on the West Coast, and adds 180 beds to our current 400-bed offering. Furthermore, it allows us to enhance our capabilities with expertise in ethnobridging and other specialty areas for hard-to-recruit study populations,” added Steve Mason, Co-Chief Operating Officer, at Altasciences.
The transaction was completed on February 12.
“This acquisition is an integral part of Altasciences’ strategic growth plan to provide a comprehensive, fully integrated early phase drug development solution to address the ever-changing outsourcing challenges of biopharmaceutical companies across the globe. We look forward to working side by side with our new team of clinical experts in California, a team that shares our values for excellence, quality, and customer focus,” explained Chris Perkin, CEO at Altasciences.
WCCT Global was founded in 1998 and has conducted over 600 Phase I studies – an area it specializes in – out of over 1,000 Phase I-IV studies the company has conducted to date.
“Joining the Altasciences team will enhance our offering while allowing us to continue the responsive delivery of quality research data to our global biopharmaceutical clients,” stated Gregory Hanson, Executive Chairman, WCCT Global.
Altasciences is a mid-size CRO/CDMO offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BearingPoint: A roadmap toward sustainability for the automotive industry
- Spar Nord upgrades its financial guidance
- Trading Update for First Quarter 2021 (prelimenary figures)
Create E-mail Alert Related CategoriesBusiness Wire, Press Releases
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!